Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

NCT03758950 is registered in ClinicalTrials.gov with Jeffrey Glassberg as lead sponsor.

NCT NCT03758950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03758950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
Lead sponsor
Jeffrey Glassberg
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2018
Completion date
May 31, 2023
Enrollment
80 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease